Next Article in Journal
Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer
Previous Article in Journal
Trajectory of End-of-Life Pain and Other Physical Symptoms among Cancer Patients Receiving Home Care
Open AccessArticle

Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells

1
Division of Medical Oncology, Department of Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Suwon 16247, Korea
2
Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
3
Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Korea
4
Department of Urology Cancer Center, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Korea
5
Department of Hospital Pathology, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Uijeongbu 11765, Korea
*
Authors to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(3), 1652-1662; https://doi.org/10.3390/curroncol28030154
Received: 15 February 2021 / Revised: 12 April 2021 / Accepted: 21 April 2021 / Published: 28 April 2021
(This article belongs to the Section Genitourinary Oncology)
APOBEC3B enzymes are endogenous carcinogenic mutagens. Metastatic urothelial carcinomas often harbor APOBEC3B-mediated mutations in which tCw to T or G substitution occurs. Here, we evaluated patient survival and CD8+ T-cell density according to APOBEC3B expression in patients with metastatic urothelial carcinoma who underwent cytotoxic chemotherapy. We performed a retrospective study on 94 patients with urothelial carcinoma who were treated with first line palliative chemotherapy. APOBEC3B expression and CD8+/CD3+ ratio of tumor-infiltrating lymphocytes were evaluated using immunohistochemistry. Kaplan–Meier survival curves were generated and the log-rank test was employed. The association between APOBEC3B expression and tumor-infiltrating lymphocytes was analyzed using Pearson’s chi-squared test. High APOBEC3B expression was detected in 71 of the 94 patients (75.5%). The median overall survival was longer in patients with high APOBEC3B expression (15 months) than in those with low expression (p = 0.045). The hazard ratio obtained based on the Cox regression analysis was 0.292 (95% confidence interval 0.118–0.723, p = 0.008). APOBEC3B expression was associated with the CD8+/CD3+ ratio (2.914, 95% confidence interval 1.030–8.249, p = 0.039). Collectively, APOBEC3B expression was an independent prognostic factor in patients with metastatic urothelial carcinoma treated with platinum-based chemotherapy. Tumor-infiltrating cytotoxic T cells were associated with APOBEC3B expression. View Full-Text
Keywords: mutagen; tumor-infiltrating T-lymphocyte; cytotoxic; urologic neoplasm; prognosis mutagen; tumor-infiltrating T-lymphocyte; cytotoxic; urologic neoplasm; prognosis
Show Figures

Figure 1

MDPI and ACS Style

Kim, H.; Kim, O.; Lee, M.A.; Lee, J.Y.; Hong, S.-H.; Ha, U-S.; Yim, K.; Kim, I.-H. Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells. Curr. Oncol. 2021, 28, 1652-1662. https://doi.org/10.3390/curroncol28030154

AMA Style

Kim H, Kim O, Lee MA, Lee JY, Hong S-H, Ha U-S, Yim K, Kim I-H. Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells. Current Oncology. 2021; 28(3):1652-1662. https://doi.org/10.3390/curroncol28030154

Chicago/Turabian Style

Kim, Hyunho; Kim, Okran; Lee, Myung A.; Lee, Ji Y.; Hong, Sung-Hoo; Ha, U-Syn; Yim, Kwangil; Kim, In-Ho. 2021. "Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells" Curr. Oncol. 28, no. 3: 1652-1662. https://doi.org/10.3390/curroncol28030154

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop